Preoperative octreotide treatment of acromegaly: Long-term results of a randomised controlled trial

European Journal of Endocrinology

Volumn 171, Issue 2, 2014, Pages 229-235

  Fougner, S L ^a   Bollerslev, J ^b,c   Svartberg, J ^d,e   Oksnes M ^f   Cooper, J ^g   Carlsen, S M ^a,h  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADENOMA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY;

ACROMEGALY; DELAYED-ACTION PREPARATIONS; HUMANS; OCTREOTIDE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84905256476     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0249     Document Type: Article

References (23)

1. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr & Vance ML. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. Journal of Clinical Endocrinology and Metabolism 2011 96 2732-2740. (doi:10.1210/jc.2011-0554)
2. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2008 93 61-67. (doi:10.1210/jc.2007-1191)
3. Holdaway IM, Bolland MJ & Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 2008 159 89-95. (doi:10.1530/EJE-08-0267)
4. Bates PR, Carson MN, Trainer PJ, Wass JA & Group UKNARS. Wide variation in surgical outcomes for acromegaly in the UK. Clinical Endocrinology 2008 68 136-142. (doi:10.1111/j.1365-2265.2007.03012.x)
5. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K & Maiter D. AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. European Journal of Endocrinology 2007 157 399-409. (doi:10.1530/EJE-07-0358)
6. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology 2004 151 439-446. (doi:10.1530/eje.0.1510439)
7. Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O'Toole S et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. Journal of Clinical Endocrinology and Metabolism 2013 98 1040-1050. (doi:10.1210/jc.2012-3072)
8. Luque-Ramirez M, Portoles GR, Varela C, Albero R, Halperin I, Moreiro J, Soto A, Casamitjana R & Spanish Multicentre Group for the Study of Acromegaly. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response. Hormone and Metabolic Research 2010 42 38-44. (doi:10.1055/s-0029-1239506)
9. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 2007 66 859-868. (doi:10.1111/j.1365-2265.2007.02825.x)
10. Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen A, Skeie S, Lund-Johansen M, Fougner SL, Bollerslev J & POTA study group. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clinical Endocrinology 2011 74 736-743. (doi:10.1111/j.1365-2265.2011.03982.x)
11. Colao A, Ferone D, Cappabianca P, Del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, de Divitiis E et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3308-3314. (doi:10.1210/jcem.82.10.4283)
12. Stevenaert A & Beckers A. Presurgical octreotide treatment in acromegaly. Acta Endocrinologica 1993 129 (Suppl 1) 18-20. (Pubitemid 23236056)
13. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP & Beitins IZ. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. Journal of Clinical Endocrinology and Metabolism 1988 67 1040-1048. (doi:10.1210/jcem-67-5-1040)
14. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism 2008 93 2984-2990. (doi:10.1210/jc.2008-0315)
15. Li ZQ, Quan Z, Tian H & Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. Journal of International Medical Research 2012 40 517-524. (doi:10.1177/147323001204000213)
16. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN & Wang HJ. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. European Journal of Endocrinology 2010 162 661-666. (doi:10.1530/EJE-09-0908)
17. Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S & Zhao Y. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocrine Journal 2010 57 1035-1044. (doi:10.1507/endocrj.K10E-203)
18. Beckers A. Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. Journal of Clinical Endocrinology and Metabolism 2008 93 2975-2977. (doi:10.1210/jc.2008- 1351)
19. Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, Pena L, Lugo G, Sangiao-Alvarellos S & Cordido F. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS ONE 2013 8 e61523. (doi:10.1371/journal.pone.0061523)
20. Hu M & Tomlinson B. Pharmacokinetic evaluation of lanreotide. Expert Opinion on Drug Metabolism & Toxicology 2010 6 1301-1312. (doi:10.1517/17425255.2010.513700)
21. Petersen H, Bizec JC, Schuetz H & Delporte ML. Pharmacokinetic and technical comparison of Sandostatin(R) LAR(R) and other formulations of long-acting octreotide. BMC Research Notes 2011 4 344. (doi:10.1186/1756-0500-4- 344)
22. Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A & Sheppard M. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. Journal of Clinical Pharmacology 2005 45 836-844. (doi:10.1177/0091270005277936)
23. Lorcy Y, Dejager S, Chanson P & French Octreotide LARG. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 2000 3 193-197. (doi:10.1023/A:1011416112730)